Subgen AI AB (FRA:52Q0)

Market Cap	1.18M
Revenue (ttm)	n/a
Net Income (ttm)	-5.74M
Shares Out	n/a
EPS (ttm)	-23.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.2665
Previous Close	0.4530
Day's Range	0.2665 - 0.3970
52-Week Range	0.1000 - 27.6000
Beta	n/a
RSI	43.87
Earnings Date	Mar 3, 2026

About Subgen AI AB

Subgen AI AB develops and commercializes diagnostic tests for monitoring and optimizing the dosage of biological drugs. The company develops a testing platform for oral health, therapeutic drug monitoring, and infectious diseases. It develops Veritope technology used to optimize the dosage of biological drugs to patients; and the MagniaReader platform. The company was formerly known as Magnasense AB and changed its name to Subgen AI AB in November 2025. Subgen AI AB was incorporated in 2019 and is based in Lund, Sweden.

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2019
• Employees: 15
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 52Q0

Financial Performance

Financial numbers in SEK